Month: June 2025

REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide choline) extended-release tablets, previously known as DCCR, at the 2025 United in Hope: International Prader-Willi Syndrome Conference. “We believe that these data reveal critical insights on the potential benefit of VYKAT XR to important subpopulations of individuals living with PWS,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “For those individuals who are managed with strict food controls, these data suggest that they had more hyperphagia symptoms at baseline yet still saw a statistically significant, clinically meaningful...

MADRID and HOLMDEL, N.J., June 25, 2025 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication solutions, today announced that it has joined ISMS Forum, Spain’s leading cybersecurity association dedicated to promoting information security, data protection, and risk management best practices. This collaboration reinforces BIO-key’s expanding presence and commitment to enhancing cybersecurity resilience and contributing to the development of robust security strategies for organizations across Spain. Through its ISMS Forum membership, BIO-key will actively participate in a range of initiatives seeking to drive innovation in identity and access management, Zero Trust security, and regulatory compliance. BIO-key will:Collaborate with members...

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that it has entered into a share purchase agreement (SPA) with Williamsburg Venture Holdings (WVH), an institutional investor. We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux Mediator™ VAR 200 to treat chronic kidney diseases. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research). The SPA allows ZyVersa to be judicious and plan for the timing and amount of any equity...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen Based on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMACAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging...

– End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled – – Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies – PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 ‘SHINE’ study (NCT03507790) of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease. In addition, proposed plans for a Phase 3 program designed to support regulatory approval of zervimesine in this patient population will...

Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and select their favorite items directly from shelves featuring one of the largest assortments of directly accessible cannabis products in the U.S. Verano will host a grand re-opening weekend-long Summer Festival celebration at Zen Leaf Cave Creek featuring giveaways, local artisan pop-ups, food trucks, and meet-and-greets with rap icons Dizzy Wright and Devin the Dude on June 28thVerano will explore scaling the new bodega-style dispensary experience across the Company’s entire Arizona retail footprint, and will offer third-party wholesale partners in-store activation opportunities in the near future The Company’s vertical Arizona operations consist of multiple cultivation and processing facilities,...

Highlights:Six diamond drillholes are planned to target the auriferous veins historically mined from the Foley Mine shaft. Drilling commenced on Wednesday, June 18, 2025, following receipt of permits and a site inspection conducted by the Nigigoonsiminikaaning First Nation. First hole intersected 1.5m of quartz vein with pyrite, chalcopyrite, sphalerite and galena.Q-Gold Resources Ltd. (TSXV: QGR) Commences Phase 3 Diamond Drilling Program at Foley Shaft, Mine Centre Project, Northwestern Ontario TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (TSXV: QGR) (“Q-Gold” or the “Company”) is pleased to announce the commencement of its Phase 3 diamond drilling program at the historic Foley Shaft, part of its Mine Centre Project located in northwestern Ontario. The drill program is the first step in a 4-stage exploration...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, one of the leading pharmaceutical companies in China. The parties have mutually agreed to conclude the strategic partnership entered into in 2021 for development, manufacturing and commercialization of imdusiran in mainland China, Hong Kong, Macau and Taiwan markets. “I would like to express our deepest thanks...

VANCOUVER, BC, June 25, 2025 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“Digital Asset Technologies” or the “Company”), a technology focused investment issuer, is pleased to announce that its portfolio company LiquidLink AI Corp. (“LinkLink”), will host a new weekly series of X (formerly Twitter) Spaces dedicated to exploring the future of Real World Assets (RWAs) on the XRP Ledger and the Bitcoin Lightning Network. The series will launch on Monday, July 7 at 11:00 AM EST, and will continue every Monday at the same time via the official LiquidLink X account: @LiquidLink_XRP. Each week, LiquidLink will host live discussions featuring developers, asset issuers, legal experts, and ecosystem builders to explore topics such as: ●How RWAs are issued and traded on the XRP Ledger ‎●Infrastructure...